ABSTRACT
Use of recombinant human thyrotropin (rhTSH) has recently been proposed to increase the sensitivity of FDG PET in the diagnosis of recurrent and metastatic cancer compared with the unstimulated setting. We have found this to be useful for increasing both the number of lesions detected and the intensity of tracer uptake in the lesions.
